Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma (VOR)
NASDAQ:VOR
VOR Stock Chart & Stats
$13.17
<$0.01(<0.01%)
At close: 4:00 PM EST
$13.17
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$2.63 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)659.14K
Market Cap
$546.82M
Enterprise Value-$67.14M
Total Cash (Recent Filing)$170.46M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)―
Beta4.95
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,519,840
10 Day Avg. Volume612,285
30 Day Avg. Volume659,142
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit39.73
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$42.00Price Target Upside218.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataStrong clinical results for telitacicept in China for myasthenia gravis and Sjögren’s disease support the therapy's effectiveness and could bolster confidence for broader development outside China.
Key Opinion Leader EndorsementPositive assessments from leading clinicians about the BAFF and APRIL mechanism and supportive clinical evidence reduce perceived program risk and can influence future prescribing and investor views.
Licensing And CommercializationVor Biopharma's exclusive rights to commercialize telitacicept outside China create a clear pathway to international market opportunity if global approvals are obtained.
Bears Say
Financing NeedAdditional funding will likely be required to support global development beyond China, creating potential dilution or financing risk for shareholders.
Regulatory DependenceApprovals in the United States, Europe and Japan hinge on a successful phase three readout, so an unfavorable trial outcome could materially delay or prevent entry into these major markets.
Single Asset ConcentrationHeavy reliance on a single drug candidate increases company-specific risk until independent global evidence validates the therapy across diverse patient populations.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $546.82M.
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is May 07, 2026 which is in 48 days.
How were Vor Biopharma’s earnings last quarter?
Currently, no data Available
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 41,519,840 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vor Biopharma?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (218.91% Upside)
$42.00 (218.91% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.97%
12-Months-Change
Fundamentals
Return on Equity
274.58%
Trailing 12-Months
Asset Growth
51.94%
Trailing 12-Months
Company Description
Vor Biopharma
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$42.00
▲(218.91% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---